World’s First Zika Vaccine Developed by Indian Scientists

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

With cold and flu season in full swing, experts say there are some simple steps you can take to protect yourself and those around you.

 Continuing its mission to provide exceptional medical care to patients across the Rio Grande Valley, DHR Health is pleased to welcome ophthalmologist Dr. Rachel Gelman to its team of healthcare providers.

To help address the ongoing need for qualified workers in the Rio Grande Valley, South Texas Health System (STHS) has renewed its support of Valley Initiative for Development and Advancement (VIDA) through a $25,000 annual grant.